Prestige BioPharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Prestige BioPharma develops biosimilars, lower-cost versions of complex biological medicines that have already been approved, targeting cancers and autoimmune diseases, and supplies them to healthcare markets globally.
It is listed on KOSPI, South Korea's main stock exchange. Its most advanced product, a biosimilar of the breast-cancer drug Herceptin marketed as Tuznue, has received full European Union approval and is preparing for launch there, while a second biosimilar of the cancer drug Avastin is in late-stage global clinical trials.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates as a pharmaceutical group that integrates research, development, and contract manufacturing through two subsidiaries, Prestige BioPharma and Prestige Biologics, providing an in-house, end-to-end service model.
Prestige BioPharma in five facts
What does Prestige BioPharma do?
Prestige BioPharma develops biosimilars, lower-cost versions of complex biological medicines that have already been approved, targeting cancers and autoimmune diseases, and supplies them to healthcare markets globally.
Where is Prestige BioPharma listed and in which sector?
Prestige BioPharma (Korean name: 프레스티지바이오파마) trades under KRX code 950210 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Biotechnology.
How large is Prestige BioPharma?
Its market capitalisation was US$243.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Prestige BioPharma's latest annual revenue and operating profit?
For fiscal year 2025, Prestige BioPharma reported revenue of US$7.7K, an operating loss of US$36.2K and net income of US$2.2K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 1875.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureSep 29
- Results of annual shareholders' meetingSep 29
- Appointment/dismissal/resignation of an independent directorSep 29
- [Amended] Annual report (2026.06)Sep 23
- Annual report (2026.06)Sep 22
- Auditor's report filedSep 21
- Resolution to convene a general shareholders' meetingSep 14
- Notice of general shareholders' meetingSep 14
- Change in shares held by the largest shareholderSep 1
- Report on securities held by executives/major shareholdersSep 1
- Report on large shareholdings (5% rule) (standard)Sep 1
- [Amended] Supply contract signed
Prestige BioPharma updated a previously disclosed supply contract with Teva Pharmaceuticals International GmbH, now worth US$896K, about 8.64% of its recent annual revenue, running through Nov 2026.
Supply contract · Aug 25 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Prestige BioPharma reported consolidated results for the fiscal year ended Jun 2026: revenue of US$17.5M (+73.33% year on year), an operating loss of US$65.5M and a net loss of US$83.1M (from a profit a year earlier).
Earnings · Aug 14 - [Amended] Supply contract signed
Prestige BioPharma updated a previously disclosed supply contract with Teva Pharmaceuticals International GmbH, now worth US$842K, about 8.64% of its recent annual revenue, running through May 2026.
Supply contract · Mar 13 - [Amended] Supply contract signedSupply contract · Jan 29